Nrf2 deficiency aggravates the increase in osteoclastogenesis and bone loss induced by inorganic arsenic.
Animals
Arsenites
/ toxicity
Bone Remodeling
/ drug effects
Female
Femur
/ drug effects
Mice
Mice, Inbred C57BL
Mice, Knockout
NF-E2-Related Factor 2
/ deficiency
Osteoclasts
/ drug effects
Osteogenesis
/ drug effects
Osteoporosis
/ chemically induced
Oxidative Stress
/ drug effects
RAW 264.7 Cells
Signal Transduction
/ drug effects
Sodium Compounds
/ toxicity
Arsenic
NFATc1
Nrf2
Osteoporosis
ROS
p38
Journal
Toxicology and applied pharmacology
ISSN: 1096-0333
Titre abrégé: Toxicol Appl Pharmacol
Pays: United States
ID NLM: 0416575
Informations de publication
Date de publication:
15 03 2019
15 03 2019
Historique:
received:
28
12
2018
revised:
06
02
2019
accepted:
07
02
2019
pubmed:
12
2
2019
medline:
20
12
2019
entrez:
12
2
2019
Statut:
ppublish
Résumé
Arsenic exposure increases the risk of various bone disorders. For instance, chronic exposure to low level arsenic can cause bone resorption by promoting osteoclast differentiation. Osteoclast precursor cells produce hydrogen peroxide after low level arsenic exposure and then undergo differentiation, producing cells which break down bone matrix. Nuclear factor E2-related factor 2 (Nrf2) regulates receptor activator of nuclear factor-κB dependent osteoclastogenesis by modulating intracellular reactive oxygen species (ROS) signaling via expression of cytoprotective enzymes. Here we tested the hypothesis that loss of Nrf2 will increase arsenic-induced bone loss. We treated 40 week-old Nrf2
Identifiants
pubmed: 30742845
pii: S0041-008X(19)30052-3
doi: 10.1016/j.taap.2019.02.003
pii:
doi:
Substances chimiques
Arsenites
0
NF-E2-Related Factor 2
0
Nfe2l2 protein, mouse
0
Sodium Compounds
0
sodium arsenite
48OVY2OC72
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
62-70Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.